Results 41 to 50 of about 74,496 (193)
Online supplementary file 2 - Supplemental material for The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review [PDF]
, 2023 Supplemental material, Online supplementary file 2, for The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review by Abrahim Abduelmula, Ahmed Bagit, Asfandyar Mufti, Katie C.Y. Yeung and Jensen Yeung in Journal of Cutaneous Medicine
Ahmed Bagit (12573562) +4 more
core +1 more source
Janus kinase inhibition in the treatment of inflammatory bowel disease [PDF]
, 2020 The aim of this thesis was to investigate Janus kinase (JAK) inhibition in the treatment of inflammatory bowel disease (IBD) from a translational perspective, reflecting both on JAK inhibition as a clinical treatment for IBD as well as on JAK inhibition ...
de Vries, L.C.S.
core +2 more sources
Tumor Biology, 2017 Long non-coding RNA HOXD-AS1 (HOXD cluster antisense RNA 1) has been demonstrated to be closely associated with the progression of several tumors. However, the biological function of HOXD-AS1 and the underlying molecular mechanism in gastric cancer are ...
Li Zheng +3 more
doaj +1 more source
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
Качественная клиническая практика, 2022 Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin +3 more
doaj +1 more source
Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia [PDF]
Cancer Research, 2006 Abstract The Bcr-Abl tyrosine kinase is the causative factor in most chronic myelogenous leukemia (CML) patients. We have shown that Bcr-Abl is associated with a cluster of signaling proteins, including Janus kinase (Jak) 2, growth factor receptor binding protein 2–associated binder (Gab) 2, Akt, and glycogen synthase kinase (GSK)-3β.
Ajoy K, Samanta +4 more
openaire +2 more sources
Journal of Lipid Research, 2010 ATP-binding cassette transporter A1 (ABCA1) is required for the lipidation of apolipoprotein A-I (apoA-I), although molecular mechanisms supporting this process remain poorly defined.
Joel Karwatsky +3 more
doaj +1 more source
Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition
JEADV Clinical Practice, 2022 Pyoderma gangrenosum (PG) is a rare, autoinflammatory disease leading to painful, hard‐to‐treat ulcers. Besides systemic glucocorticoids, a plethora of classic immunosuppressants, biologics and small molecules have been reported to improve PG disease ...
Sebastian Sitaru +2 more
doaj +1 more source
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations. [PDF]
J Allergy Clin Immunol, 2019 Background: Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine signals in the regulation of hematopoiesis and immunity. JAK2 clinical mutations cause myeloproliferative neoplasms and leukemia, and the mutations strongly concentrate
Hammarén HM +5 more
europepmc +3 more sources
Janus Kinase 2: An Epigenetic 'Writer' that Activates Leukemogenic Genes [PDF]
Journal of Molecular Cell Biology, 2010 Activation of Janus kinase 2 (JAK2) plays a critical role in normal hematopoiesis and leukemogenesis. Dawson et al. (2009; JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819-822) report that JAK2 performs this function by displacing the heterochromatin protein HP1α from chromatin through phosphorylation of histone ...
Jin, He, Yi, Zhang
openaire +2 more sources
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation [PDF]
, 2009 We report two patients with peripheral vascular disease requiring multiple bilateral radiologic and surgical interventions, and whose disease was unresponsive to conventional anticoagulation and antiplatelet therapy.
Edmondson, Robert A. +5 more
core +1 more source